Arno Stellingwerf, Davita Bosveld, Lieke Jäkel, Anna M. De Kort, Benno Küsters, C. Klijn, Floris H. B. M. Schreuder, H. B. Kuiperij, Marcel M. Verbeek
tlooto Summary
Investigation of BSG expression in CAA brain tissue with immunohistochemistry and as cerebrospinal fluid biomarker for BBB dysfunction in patients with CAA found it to be a viable biomarker for BBB dysfunction.
Abstract
Blood–brain barrier (BBB) dysfunction may be involved in the pathophysiology of neurodegenerative disorders, including sporadic cerebral amyloid angiopathy (CAA). Because basigin (BSG) may induce activity of matrix metalloproteinases and thereby BBB breakdown, we investigated BSG expression in CAA brain tissue with immunohistochemistry and as cerebrospinal fluid biomarker for BBB dysfunction in patients with CAA.
Citation format
STELLINGWERF, Arno, et al. Evaluating basigin as a potential biomarker of blood–brain barrier dysfunction in cerebral amyloid angiopathy. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2026, 52(1): e70064.